Miravirsen (INN; codenamed SPC3649) is an experimental drug for the treatment of hepatitis C, being developed by Santaris Pharma.

[1] Miravirsen had been given by subcutaneous injection in early clinical trials as of 2017.

[1] There is some evidence that the 5'-UTR region mutates under repeated exposure to miravirsen.

[1] Miravirsen is a modified oligonucleotide consisting of a chain of 15 nucleotides, the base sequence of which is designed to selectively bind to miR-122.

[1][2] Seven of the 15 sugar units are deoxyriboses, and the other eight are riboses with an additional bridge between the 2' oxygen and the 4' carbon atoms; this makes the molecule a locked nucleic acid.